Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension
Key facts
- Who runs it
- The First Affiliated Hospital with Nanjing Medical University
- Where
- China3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 103 people enrolled
- Started
- 1 Nov 2021
- Ended
- 20 Nov 2023
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- focused power ultrasound mediate inferior perirenal adipose tussue modification
- sham-control group
- Record updated
- 7 December 2023
- Why it stopped
- Till interim analysis, 100 cases were enrolled, 71 of which during the COVID-19. Affected by epidemic control policy, 58 cases had examination window exceeded or missed, causing significant impact on endpoints, so we decided to terminate the trial.
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Individual has office systolic blood pressure (SBP) ≥ 140 mmHg and <180 mmHg when receiving a medication regimen of one, two, or three antihypertensive medication classes;
- Individual has 24-hour Ambulatory Blood Pressure Monitoring (ABPM) average SBP≥135 mmHg;
- The anteroposterior, transverse and axial diameters of inferior perirenal fat pad measured by ultrasound should be at least 20mm;
- Individual is willing to sign the informed consent of the study
Who cannot take part
- Individual is diagnosed as secondary hypertension (e.g. renal parenchymal hypertension, renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing's syndrome, aortic coarctation, obstructive sleep apnea hypopnea syndrome);
- Individual has history of kidney and or kidney surrounding tissue surgery
- Individual has myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack within 6 months of enrollment
- Individual has type 1 diabetes or poorly-controlled type 2 diabetes;
- Individual has severe structural heart disease (e.g. heart valve disease, cardiomyopathy, congenital heart disease)
- Individual has infected waist skin
- Individual has malignant tumor
- Individuals has impairment of liver or kidney function (ALT, AST or creatinine is greater than 2 times of the upper limit of normal reference)
- Individual has uncontrolled thyroid dysfunction
- Individual has urinary calculi and/or hematuria;
- Individual has atrial fibrillation
- Individual has second degree and above atrioventricular block;
- Individual has abnormal coagulation function
- Individual is pregnant, nursing or planning to be pregnant
- Individual is unwilling to sign informed consent
- Individual fails to complete the screening period
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This randomized, double blinded, sham-control trial aims to evaluate the efficacy and safety of a novel focused power ultrasound mediated inferior perirenal adipose tissue modification therapy for essential hypertension.
The 2 groups in the trial
- intervention groupTreatment being tested
In intervention group, participants will receive the whole peri-renal fat modification therapy (including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting and initiating)
Treatment: focused power ultrasound mediate inferior perirenal adipose tussue modification
- sham-control groupSham treatment, for comparison
In sham control group, participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension: a Multicenter, Randomized, Double-blinded Controlled Trial. PARADISE Study
- Publications
- Record updated
- 7 December 2023